Unnamed AI Drug Discovery Startup (Miles Wang)
Category: AI in Biotech / Drug Discovery
Pre-launch AI drug discovery startup founded by ex-OpenAI researcher Miles Wang, focused on developing AI models for drug repurposing. Unnamed AI Drug Discovery Startup (Miles Wang) was founded in 2026. The company is led by Miles Wang (Miles K. Wang). Based in San Francisco, USA. Team size: 1-10.
- Founded
- 2026
- Headquarters
- San Francisco, USA
- Team size
- 1-10
Value proposition
Applying transformer-based AI models and reinforcement learning techniques from frontier AI research to accelerate drug discovery, with an initial focus on drug repurposing — finding new therapeutic uses for existing FDA-approved drugs and previously failed clinical candidates.
Products and solutions
AI models for drug repurposing (in development, pre-product stage), transformer architectures applied to biological data and molecular prediction
Unique value
Founded by a top OpenAI researcher with deep expertise in RL, AI safety, and AI-for-science; drug repurposing approach skips years of early safety testing, enabling faster time-to-revenue; backed by Lightspeed at a $2B pre-launch valuation
Target customer
Pharmaceutical companies, biotech firms, and clinical research organizations seeking faster drug development pipelines
Industries served
Biotech & Health, AI Drug Discovery, Pharmaceuticals
Technology advantage
Leverages frontier AI techniques (transformer models, RL, scalable oversight) developed at OpenAI; co-authored FrontierScience benchmark evaluating AI's ability to perform expert-level scientific tasks; wet-lab research on AI-guided biological protocols showing 79x efficiency gains
How they differentiate
Focus on drug repurposing (finding new uses for existing/failed drugs) rather than de novo drug design; founded by OpenAI RL researcher rather than biotech veterans; pre-product/pre-launch stage with $2B valuation before naming the company
Main competitors
Chai Discovery (raised $400M at $3.8B valuation, also OpenAI alumni), Isomorphic Labs (Google DeepMind spinout, raised $2.1B Series B), Recursion Pharmaceuticals
Major milestones
July 2026: TechCrunch reports Miles Wang is in talks to leave OpenAI and launch AI drug discovery startup at $2B valuation with $200M from Lightspeed
Market positioning
Premium AI drug discovery spinout leveraging OpenAI talent and brand; positioned alongside Chai Discovery and Isomorphic Labs in the frontier AI + biology space
Geographic focus
United States (San Francisco Bay Area)
About Miles Wang (Miles K. Wang)
Ex-OpenAI Researcher (RL Team, March 2024–July 2026); Harvard University CS (dropped out). Co-authored FrontierScience benchmark and AI-for-biology research at OpenAI.
Official website: https://mileskwang.com/